Avience Biomedicals Ltd. logo

Avience Biomedicals was incorporated on December 23, 2019. The company is engaged in the manufacturing of in-vitro diagnostic (IVD) products and medical devices from its facility in Noida, Uttar Pradesh. Its products support the detection of diseases, infections, and medical conditions through laboratory, healthcare, and home-based diagnostic testing applications

Bidding Dates
18 Jun 2026 - 22 Jun 2026
Subscription
355.06x Oversubscribed
Minimum InvestmentMinimum LotMaximum LotLot SizeNumber of SharesIssue Price BandPost Issue Promoter Holding %Issue SizeIPO Document
₹235,200226001.5 M₹196 - ₹20864.59 %₹284.9 M - ₹302.4 MRHP DOC

Avience Biomedicals IPO SUBSCRIPTION STATUS

22 Jun '26
Total355.06x
Retail Individual Investor528.55x
HNI (NII) Investors789.97x
Qualified Institutional Buyers103.14x

Avience Biomedicals IPO overall subscription rate was 355.06 times the total available shares

Avience Biomedicals IPO retail subscription rate was 528.55 times in the retail segment

Avience Biomedicals IPO non-institutional investor subscription rate was 789.97 times in the non-institutional investor category

Avience Biomedicals IPO Qualified Institutional Bidder subscription rate was 103.14 times the available shares for Qualified Institutional Bidder

DayRetail Individual InvestorHNI (NII) InvestorsQualified Institutional Buyers
Category Reservation35%15%50%
22 Jun 2026
(Day 3)
528.55x789.97x103.14x
19 Jun 2026
(Day 2)
76.41x88.08x0.01x
18 Jun 2026
(Day 1)
20.06x17.75x-

Avience Biomedicals FINANCIALS

Period Revenue from Operations (Rs in crore) Net Profit (Rs in crore) Cash Flow from Operations (Rs in crore) Free Cash Flow (Rs in crore) Margins
10MFY26 41.8 5.7 2.8 -6.4 24.7%
FY25 45.2 7.2 3.6 -4.7 25.2%
FY24 24.0 2.1 1.0 -2.9 17.0%

Avience Biomedicals IPO SUBSCRIPTION STATUS DETAILS

Avience Biomedicals had 1.5 M shares on offer

Avience Biomedicals IPO offer price was in the range ₹196 - ₹208

Avience Biomedicals IPO minimum Investment was ₹235200

Avience Biomedicals IPO issue size was ₹ 284.9 M - ₹ 302.4 M

Avience Biomedicals had a minimum lot size of 600 Shares per application

Avience Biomedicals NUMBER OF SHARES ON OFFER

Total1.5 M
Fresh Issue1.5 M
Offer for Sale0
Post Issue Promoter Holding %64.59 %

Avience Biomedicals IPO IMPORTANT DATES

Issue Open Date18 Jun 2026
Issue close Date22 Jun 2026
Allotment Date23 Jun 2026
Refund Date24 Jun 2026
Demat Account Credit Date24 Jun 2026
Listing Date25 Jun 2026
Listing on Exchange(s)NSE
Avience Biomedicals Allotment StatusExchange/ Registrar

Avience Biomedicals IPO subscription opened on 18 Jun 2026, and closed on 22 Jun 2026

IPO allotment for Avience Biomedicals was finalized on Tuesday, 23 Jun 2026

IPO listing for Avience Biomedicals was on NSE on Thursday, 25 Jun 2026

Avience Biomedicals IPO LISTING GAINS

Issue Price (adjusted)208.0
Listing Open Price395.2
Listing Close Price414.9
Listing Gain%90.0%
Current Gain%26.9%

Avience Biomedicals Peer

StockStock PriceMarket Cap (Rs crore)PE TTMPEG TTMPS TTMROE%ROA%Annual Revenue (Rs crore)Annual Revenue Growth %Annual Net Profit (Rs crore)Annual Net Profit Growth %EPS TTMEPS TTM Growth %
Avience Biomedicals Ltd.263.8144.716.50.82.727.911.252.814.98.8211621
Tarsons Products Ltd.303.41614.3217.3-3.43.52.21.2446.79.414.3-51.91.4-63.9
Hemant Surgical Industries Ltd.590.3769.742.313.26.6237.7112.718.2126.214
Fabtech Cleanrooms Ltd.414.3510.432.315.28.5221.746.915.81912.8
Prevest Denpro Ltd.369.3443.321.61.45.716.415.476.714.420.512.917.115.1
QMS Medical Allied Services Ltd.170328.827.6-0.41.711.45.6173.910.311.9-1.56.2-73.9

Avience Biomedicals INFORMATION ON IPO ISSUE

About Avience Biomedicals

Avience Biomedicals was incorporated on December 23, 2019. The company is engaged in the manufacturing of in-vitro diagnostic (IVD) products and medical devices from its facility in Noida, Uttar Pradesh. Its products support the detection of diseases, infections, and medical conditions through laboratory, healthcare, and home-based diagnostic testing applications

Object of the Issue

  • Part finances the capital expenditure towards setting up of a new manufacturing unit Gautam Buddha Nagar, Uttar Pradesh
  • Funding the working capital requirement of the company
  • To meet out the general corporate purposes

Avience Biomedicals - PROMOTERS

Name
Dharam Deo Choudhary
Ram Nagina Choudhary
Deepa Choudhary
Janardan Pal

Avience Biomedicals - MANAGEMENT & LEADERSHIP

NameDesignation
Dharam Deo ChoudharyChairman & Managing Director
Ram Nagina ChoudharyWhole Time Director
Deepa ChoudharyDirector
Janardan PalDirector
Om Prakash PalIndependent Director
Pankaj SharmaIndependent Director

Avience Biomedicals Book Running Lead Manager

Fintellectual Corporate Advisors Private Limited

ipo@fintellectualadvisors.com

Avience Biomedicals Registrar to the Offer

Skyline Financial Services Private Limited

ipo@skylinerta.com

Avience Biomedicals Strengths

Innovative product portfolio

The company offers a comprehensive portfolio of IVD rapid diagnostic tests and medical devices, including solutions for infectious disease detection, haematology, and biochemistry analysis. It also strengthens its product range through its association as a channel partner for Mindray, providing advanced diagnostic and laboratory equipment to healthcare providers

Strength

End to end support

The company has a dedicated team of service engineers that provides end-to-end support, including equipment installation, user training, and maintenance services. This enables healthcare facilities and laboratories to operate efficiently with minimal downtime and improved diagnostic productivity

Strength

Talented workforce & efficient operations

The company is supported by a skilled workforce across manufacturing, quality assurance, regulatory affairs, and technical support, with a strong focus on continuous training and innovation. Its efficient manufacturing processes and adherence to quality standards enable timely product delivery while maintaining flexibility to meet evolving healthcare market requirement

Strength

Avience Biomedicals Risks

Inventory management risk

The company’s medical devices and consumables have a limited shelf life, making timely production, storage, and distribution critical to its operations. Any disruption in warehousing, logistics, or supply chain activities could lead to inventory losses, delayed deliveries, and an adverse impact on business performance and financial condition

Risk

Competition & customer retention risk

The company’s revenue depends on the continued success of its existing product portfolio and customer relationships, as well as the market acceptance of new products and innovations. Any decline in product competitiveness, loss of key customers, or failure to adapt to changing market demands could adversely affect its revenue, market position, and financial performance

Risk

Depend on third-party logistics

The company relies on third-party logistics and transportation services for the timely movement of raw materials and finished products. Any disruption caused by transportation delays, accidents, natural disasters, or external factors could increase costs, affect supply chain efficiency, and adversely impact operations and customer deliveries

Risk

IPO FAQs

  • The promoters of the company are Dharam Deo Choudhary, Ram Nagina Choudhary, Deepa Choudhary and Janardan Pal.
  • The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
  • The price band of the IPO is Rs 196.0 - 208.0.
  • The IPO application opens on Jun 18, 2026 and closes on Jun 22, 2026.
  • The minimum lot size for the IPO is 1200. The maximum lot size for the IPO is 1200.
  • For all category investors, the minimum application amount for this IPO is Rs. 235,200.0, the maximum value for this IPO is Rs 249,600.0.
  • This IPO will be allotted on Jun 23, 2026.
  • The refund will be credited to your account on Jun 24, 2026.
  • The allotted shares will be credited to your demat on Jun 24, 2026.
  • Avience Biomedicals Ltd.’s shares listed on the stock exchanges on Jun 25, 2026.